Form 8-K - Current report:
SEC Accession No. 0001104659-26-086406
Filing Date
2026-07-24
Accepted
2026-07-23 19:54:03
Documents
11
Period of Report
2026-07-21
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2621232d1_8k.htm   iXBRL 8-K 24295
  Complete submission text file 0001104659-26-086406.txt   190038

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA otlk-20260721.xsd EX-101.SCH 3047
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20260721_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20260721_pre.xml EX-101.PRE 22380
14 EXTRACTED XBRL INSTANCE DOCUMENT tm2621232d1_8k_htm.xml XML 3193
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 261198194
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)